Founder, Chairman & CEO
Dr. Jaikaria is trained as a medical scientist and brings over twenty years of Financial Markets, business leadership & deep scientific experience to SGN Nanopharma. Dr. Navdeep Jaikaria founded SGN and its Indian subsidiary, New India Biopharma Pvt. Ltd., in 2010 and has successfully guided SGN into a cutting edge, commercial stage, nanotherapeutics company. Before founding SGN, Dr. Jaikaria was a consistently top ranked Biotechnology Equity Research Analyst on Wall Street and won several distinctions including one of the five best stock-pickers in Biotechnology in the Wall Street Journal’s annual “Best on the Street” Analysts survey in 2007. During his tenure on Wall Street, he held several positions. He was a Principal and served as a Managing Director & Head of Equity Research for Rodman and Renshaw, New York; Senior Vice President & Senior Biotechnology Equity Research Analyst at Leerink Swann & Co.; Senior Equity Research Analyst covering large and mid-cap biotechnology companies at Mehta Partners – a global health care hedge fund with over $100MM under management. He covered over 50 Biotechnology and Biopharmaceutical companies and his coverage universe spanned several therapeutic class areas. Dr. Jaikaria served on several industry-focused and investor panels and provided input to the United States Senate Health Committee on Bio-defense issues. His opinions were widely cited in print and broadcast media including The Wall Street Journal, Financial times, Businessweek, Forbes, CNNfn, CNBC and CNN. Dr. Jaikaria obtained his B.Sc. from All India Institute for Medical Sciences, New Delhi in Human Biology (Rank II), Ph.D. at the New York Medical College in Cell Biology & Anatomy and post-doctoral fellowship at The Rockefeller University, New York.
Vice President, R&D and Regulatory Affairs
Dr. Alam has over 38 years of pharma experience in the US. He was previously a Senior VP of New Business development at Akorn Pharmaceuticals. Dr. Alam has more than 25 issued patents and has helped launch about 200 products in the US. At Unimed, he helped develop and commercialize synthetic dronabinol [Schedule I drug- ~65% of cannabis] and soft gel capsule formulation, Marinol (Cannibis derived; synthetic version of delta-9-THC) for the FDA approved indications- anti-emetic in cancer and appetite stimulant in AIDS patients. Dr. Alam also helped develop the generic version of Marinol capsules while at Akorn and conduct the BE trial against Marinol to support ANDA approval.
Senior Vice President – Global Operations
Accomplished business leader with over 25 years of experience in Pharma. Was formerly Managing Director of Stryker India and Sandoz India. Has held senior leadership positions globally including Europe, Africa besides India. He has a BE with honors (Electronics) and an MBA from University of Delhi.
Chief Business Officer
Mr. Sanjiv Kapur is a successful entrepreneur with over 25 years of production, marketing and business development experience. He has a BE in Mechanical Engineering and a Masters in Environmental Engineering from University of Southern California.
Chief Financial Officer
Mr. Srivastava brings over 15+ years of cross border experience in corporate finance and executive leadership; 9+ years of working at JP Morgan investment bank and 7+ years of working as the CFO for several small to mid size companies from healthcare, technology to retail. He also served as the CFO for a global not-for-profit in US and India that ran a healthcare NGO in India. Academic background includes a BS in Chemical Engineering from University of Rochester and a MBA in Finance & Marketing from New York University – Stern School of Business.
Dr. Singhvi brings over 20 years of Big Pharma and Biotech Senior Management, Manufacturing and R&D experience to SGN. He serves currently as the Chief Operating Officer for Takeda Vaccines and is responsible for global supply of Takeda vaccines. He has deep experience in both vaccine development and manufacturing. Before joining Takeda, Dr. Singhvi was President and CEO of Novavax (NVAX; Nasdaq-listed ). His professional career began at Merck & Co in 1994, where he held several key positions in R&D and manufacturing with increasing responsibilities in the vaccine development process. This included co-lead of the varicella-zoster virus vaccine project team and oversaw the development of Varivax®III (chickenpox vaccine), and Zostavax® (Shingles vaccine). Dr. Singhvi graduated as the top ranked chemical engineer from IIT Kanpur, India; obtained his ScD in chemical engineering from MIT and an MBA from the Wharton School, the University of Pennsylvania, where he graduated as a Palmer Scholar.
Dr. Sunil Gupta, is a leading, nationally recognized retinal surgeon in the US, a successful entrepreneur, and a health care pioneer. He founded the Retina Specialty Institute, and is the co-founder and chief medical officer of USRetina—one of the largest associations of retina physicians in the United States—as well as the founder, chairman and chief medical officer of IRIS: Intelligent Retinal Imaging Systems, an FDA-cleared, cloud based, telemedicine tool for assessment of retinal eye disease in the primary care setting. The award-winning IRIS team is on a mission to end preventable blindness due to Diabetic Retinopathy and other conditions. Dr. Gupta was the past chairman of the Andrews Institute Ambulatory Surgery Center and serves on the board of the Andrews Research & Education Institute. Dr. Gupta has participated in over 30 clinical studies.
Dr. Gupta presently serves on the Advisory Boards of several leading Multinational Pharmaceutical companies including Novartis, Allergan and Genentech. He obtained his B.Sc. in Chemical Engineering from the University of Washington, Seattle and his MD from University of Cincinnati College of Medicine.
Professor of Pharmaceutics, in the Department of Drug Discovery and Development at Harrison School of Pharmacy, Auburn University. He has published over 110 research papers and scientific abstracts till date. He has been serving as Editorial Board member for five journals and manuscript reviewer for more than 30 journals in Pharmaceutics and drug delivery research areas. His main research areas include topical and transdermal delivery, solubility improvement of BCS class II drugs. Currently his laboratory is doing research on the skin permeability of various topical nanoparticle based systems.
Dr. Miller is a leading plastic surgeon in Boston who serves on the faculty staff of the Harvard Medical School with full operating privileges at Beth Israel Deaconess Hospital, New England Baptist Hospital (Chief of Plastic Surgery), and the Massachusetts Eye and Ear Infirmary. He is actively involved in the development of new skin care technologies and cosmetic products. Dr. Miller is an investor in SGN and is helping to develop the anti-wrinkle & Alopecia franchises.
Dr. Warren is a well-known plastic and Craniofacial surgeon and the Vice-Chairman of Plastic Surgery, New York University Medical Center. Dr. Warren is on the editorial Board of several International Medical Journals and has over 200 publications. Dr. Warren has diverse interests including: tissue engineering, outcomes research, and regenerative medicine. Dr. Warren is an investor in SGN and is helping us develop the anti-wrinkle & Alopecia franchises.
A leading ophthalmologist in India Dr. Reddy is the Founder and Co-Chairman of a super specialty eye care hospital in Hyderabad which is India’s first Lasik Centre. He is a member of the Advisory Board of Bausch & Lomb and an investor in SGN.
Internationally known ophthalmologist and corneal and refractive surgery specialist. He is currently Associate Professor of ophthalmology at Rush University Medical Center in Chicago,IL. In addition to a busy clinical and surgical practice, Dr. Majmudar is an active participant in clinical research and is an active member of the American Society of Cataract and Refractive Surgery as well as the American Academy of Ophthalmology. He recently received the Academy’s Senior Achievement Award. He is an International Council Representative from the United States for the International Society of Refractive Surgery. Dr. Majmudar also serves on the medical advisory board for several commercial entities. R. Majumdar is an investor in SGN.
Over 25 years of experience in federal government contracting and commercial sales in business development, capture management, proposal development and management, technical solution development, and program implementation and management. Mr. Adivi brings a unique combination of technical talent, with his strong engineering background, and years of business experience to successfully capture technology business, as evidenced by the hundreds of millions dollars of business he has won for his companies over his career. He has successfully served in key technology management roles at Canonical, URS, NCI, Intelect, Southwestern Bell Technology Resource Inc., Texas Instruments, and Lockheed Missiles and Space Company. Mr. Adivi was co-founder of Vesta Broadband Services, a startup that specialized in developing and licensing video-delivery infrastructure software. He received a Bachelor of Technology (Honors) Degree in Manufacturing Engineering from the Indian Institute of Technology, Kharagpur, India, and a Master of Science Degree in Mechanical Engineering from the University of Hawaii at Manoa.
Dr. Patel is an accomplished leader and a successful entrepreneur. He brings strong execution skills and over 23 years of manufacturing & international business development experience to SGN. In 1992, Dr. Patel founded National Biochemicals Corp which manufactures and supplies raw materials to the life science industry. He served as its President & CEO until Feb 2015, when he sold the company to VWR International. Dr. Patel obtained his Ph.D. in Biochemistry in 1980 from University of Saskatchewan, Canada. He is an investor in SGN.